Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,201 to 1,220 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis. | Front Immunol | 2021 | 34777388 | PubTator, text mining | PubMed |
| Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. | Cancers (Basel) | 2021 | 34771615 | PubTator, text mining | PubMed |
| Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. | Cancer Cell | 2021 | 34767762 | PubTator, text mining | PubMed |
| Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. | MedComm (2020) | 2021 | 34766141 | PubTator, text mining | PubMed |
| NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. | Front Oncol | 2021 | 34765554 | PubTator, text mining | PubMed |
| Prioritisation of Candidate Genes Underpinning COVID-19 Host Genetic Traits Based on High-Resolution 3D Chromosomal Topology. | Front Genet | 2021 | 34759959 | PubTator, text mining | PubMed |
| The Clinical Significance and Immunization of MSMO1 in Cervical Squamous Cell Carcinoma Based on Bioinformatics Analysis. | Front Genet | 2021 | 34759952 | PubTator, text mining | PubMed |
| Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. | EBioMedicine | 2021 | 34758415 | PubTator, text mining | PubMed |
| Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. | Nat Commun | 2021 | 34737267 | PubTator, text mining | PubMed |
| Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. | Acta Pharm Sin B | 2021 | 34729298 | PubTator, text mining | PubMed |
| BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism. | J Immunother Cancer | 2021 | 34725211 | PubTator, text mining | PubMed |
| Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls. | Front Med (Lausanne) | 2021 | 34722568 | PubTator, text mining | PubMed |
| A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma. | Dis Markers | 2021 | 34721731 | PubTator, text mining | PubMed |
| CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer. | Aging (Albany NY) | 2021 | 34717291 | PubTator, text mining | PubMed |
| Genomic Instability Promotes the Progression of Clear Cell Renal Cell Carcinoma Through Influencing the Immune Microenvironment. | Front Genet | 2021 | 34712264 | PubTator, text mining | PubMed |
| Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. | Cell Discov | 2021 | 34697287 | PubTator, text mining | PubMed |
| Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. | Front Cell Dev Biol | 2021 | 34692696 | PubTator, text mining | PubMed |
| TNF Patterns and Tumor Microenvironment Characterization in Head and Neck Squamous Cell Carcinoma. | Front Immunol | 2021 | 34691075 | PubTator, text mining | PubMed |
| Trial watch: intratumoral immunotherapy. | Oncoimmunology | 2021 | 34676147 | PubTator, text mining | PubMed |
| A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. | Front Immunol | 2021 | 34675941 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=61